Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluticasone/formoterol BAI versus Ultibro Breezhaler in fixed airflow obstruction with elevated eosinophils
2015-002046-31Phase 3Completed
- Sponsor
- Mundipharma
- Start
- Dec 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of fluticasone propionate, formoterol, indacaterol and glycopyrronium in Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome (ACOS) and Airflow Limitation (2 arms), sponsored by Mundipharma. Primary endpoint: Change from baseline in eosinophil count in induced sputum at Week 6. Started Dec 2015; status: completed.
02
Drugs
fluticasone propionateformoterolindacaterolglycopyrronium
03
Conditions
Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome (ACOS)Airflow Limitation
Beyond the preview
Go deeper on 2015-002046-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002046-31.